Kanagawa, Japan

Kentaro Rikimaru

USPTO Granted Patents = 8 

 

Average Co-Inventor Count = 5.6

ph-index = 3

Forward Citations = 34(Granted Patents)


Location History:

  • Osaka, JP (2013)
  • Kanagawa, JP (2019 - 2024)

Company Filing History:


Years Active: 2013-2025

Loading Chart...
Loading Chart...
8 patents (USPTO):Explore Patents

Title: Kentaro Rikimaru: Innovator in Pharmaceutical Research

Introduction

Kentaro Rikimaru is a prominent inventor based in Kanagawa, Japan. He has made significant contributions to the field of pharmaceutical research, particularly in the development of compounds that target orexin type 2 receptors. With a total of eight patents to his name, Rikimaru's work is paving the way for new therapeutic options for conditions such as narcolepsy.

Latest Patents

Rikimaru's latest patents include a substituted piperidine compound and a heterocyclic compound, both of which exhibit orexin type 2 receptor agonist activity. The substituted piperidine compound is particularly noteworthy for its potential use as a prophylactic or therapeutic agent for narcolepsy. Similarly, the heterocyclic compound also shows promise in the treatment of this condition, highlighting Rikimaru's focus on addressing sleep disorders through innovative chemical solutions.

Career Highlights

Kentaro Rikimaru is currently employed at Takeda Pharmaceutical Company Limited, where he continues to advance his research in pharmacology. His work has not only contributed to the scientific community but has also positioned Takeda as a leader in the development of novel treatments for sleep-related disorders.

Collaborations

Rikimaru collaborates with esteemed colleagues such as Tatsuhiko Fujimoto and Hiromichi Sugimoto. These partnerships enhance the research environment and foster innovation within the pharmaceutical sector.

Conclusion

Kentaro Rikimaru's contributions to pharmaceutical research, particularly in the area of orexin type 2 receptor agonists, demonstrate his commitment to improving therapeutic options for narcolepsy. His innovative work at Takeda Pharmaceutical Company Limited continues to impact the field positively.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…